Vivos Therapeutics (VVOS) Director Leonard Sokolow Receives Option Grant

What Happened
Leonard J. Sokolow, a director of Vivos Therapeutics, received a grant of 12,000 stock options on September 14, 2026. The grant is reported as an award (derivative) with a reported acquisition price of $0.00 (typical for option grants). One-half (6,000 options) vested immediately; 3,000 options vest on Sept 30, 2026 and 3,000 on Dec 31, 2026. The options are exercisable for a 10‑year period from the grant date.

Key Details

• Transaction date: 2026-09-14 (reported on Form 4 filed 2026-09-18). The filing occurred four days after the grant (appears later than the typical two-business-day Form 4 deadline).
• Award: 12,000 stock options; reported acquisition price $0.00 (derivative award).
• Vesting: 6,000 immediate; 3,000 on 2026-09-30; 3,000 on 2026-12-31.
• Exercise term: 10 years from the grant date.
• Other notes from filing: reflects prior expirations of 667 options (6/19/2025) and 1,200 options (8/5/2026) that expired unexercised.
• Post-transaction beneficial ownership (total shares/options owned after this grant) not specified in the excerpt provided.

Context
This was an option grant (an award), not an open-market purchase or sale. Option awards are common compensation for directors and do not by themselves indicate immediate buying or selling of stock. Because one-half vested immediately, the director can exercise that vested tranche right away (subject to payment of any exercise price and other plan terms). The late filing note is factual — Form 4s are generally required within two business days of the transaction, so the four-day gap is worth noting for timeliness but does not change the substance of the grant.